On Monday, Emergent Biosolutions Inc (NYSE: EBS) was -7.03% drop from the session before settling in for the closing price of $6.83. A 52-week range for EBS has been $4.02 – $15.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 469.57%. With a float of $51.92 million, this company’s outstanding shares have now reached $54.50 million.
Let’s determine the extent of company efficiency that accounts for 900 employees. In terms of profitability, gross margin is 31.6%, operating margin of -5.65%, and the pretax margin is -6.49%.
Emergent Biosolutions Inc (EBS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Emergent Biosolutions Inc stocks. The insider ownership of Emergent Biosolutions Inc is 4.35%, while institutional ownership is 66.76%. The most recent insider transaction that took place on May 23 ’25, was worth 49,417. In this transaction Director of this company sold 7,844 shares at a rate of $6.30, taking the stock ownership to the 86,431 shares. Before that another transaction happened on May 23 ’25, when Company’s Director proposed sale 7,844 for $6.30, making the entire transaction worth $49,409.
Emergent Biosolutions Inc (EBS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 469.57% per share during the next fiscal year.
Emergent Biosolutions Inc (NYSE: EBS) Trading Performance Indicators
You can see what Emergent Biosolutions Inc (EBS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.36. Likewise, its price to free cash flow for the trailing twelve months is 3.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.71, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach 1.25 in one year’s time.
Technical Analysis of Emergent Biosolutions Inc (EBS)
Looking closely at Emergent Biosolutions Inc (NYSE: EBS), its last 5-days average volume was 2.53 million, which is a jump from its year-to-date volume of 1.25 million. As of the previous 9 days, the stock’s Stochastic %D was 63.12%.
During the past 100 days, Emergent Biosolutions Inc’s (EBS) raw stochastic average was set at 33.36%, which indicates a significant increase from 32.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.54% in the past 14 days, which was lower than the 92.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.96, while its 200-day Moving Average is $7.69. However, in the short run, Emergent Biosolutions Inc’s stock first resistance to watch stands at $6.75. Second resistance stands at $7.14. The third major resistance level sits at $7.41. If the price goes on to break the first support level at $6.09, it is likely to go to the next support level at $5.82. Now, if the price goes above the second support level, the third support stands at $5.43.
Emergent Biosolutions Inc (NYSE: EBS) Key Stats
There are 54,278K outstanding shares of the company, which has a market capitalization of 344.66 million. As of now, sales total 1,044 M while income totals -190,600 K. Its latest quarter income was 222,200 K while its last quarter net income were 68,000 K.
